Saturday 17 October 2026
Export SANA’s income statement to Excel — free account
Sana Biotechnology, Inc.
SANA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.6% and free cash flow fell 5.46%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.27
0.21
−8.47%
Follow SANA
Sana Biotechnology, Inc. (SANA) P/E ratio
Sana Biotechnology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DNA Ginkgo Bioworks Holdings, Inc. compare | n/m |
| SANA Sana Biotechnology, Inc. | n/m |
| ACHV Achieve Life Sciences, Inc. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | n/m |
| LXRX Lexicon Pharmaceuticals, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| GERN Geron Corporation compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | n/m |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)